AI Article Synopsis

Article Abstract

Acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis, mainly affecting distal phalanges of hands and feet. Many therapeutic options exist; however, it tends to be resistant to treatment. We report a 26-year-old man presented with a very severe psoriatic arthritis associated with ACH. Although this patient was resistant to a first line treatment (glucocorticoids and methotrexate), a rapid and dramatic improvement was observed after adalimumab was introduced. The effectiveness and tolerance of the treatment were maintained during the 12-month period of follow-up. This is the first report of the efficacy of adalimumab on ACH in a patient presented with psoriatic arthropathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047268PMC
http://dx.doi.org/10.5152/eurjrheum.2015.0072DOI Listing

Publication Analysis

Top Keywords

acrodermatitis continua
8
continua hallopeau
8
psoriatic arthritis
8
resistant treatment
8
ach patient
8
successful treatment
4
treatment acrodermatitis
4
hallopeau associated
4
associated psoriatic
4
arthritis adalimumab
4

Similar Publications

Background: Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant predominantly affects the distal phalanges of the fingers and toes. However, data on aggravating factors and treatment outcomes is limited.

Objective: This study aims to analyze the aggravating factors and treatment outcomes of ACH in a three-tertiary-hospital in South China.

View Article and Find Full Text PDF

Is tofacitinib monotherapy also effective for the treatment of Acrodermatitis continua of Hallopeau?

Australas J Dermatol

December 2024

Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Cultivation for Arthritis Diagnosis and Treatment, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!